Octavia Wealth Advisors LLC increased its stake in NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 5.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,487 shares of the computer hardware maker's stock after acquiring an additional 8,531 shares during the period. NVIDIA makes up ...
Octavia Wealth Advisors LLC increased its stake in NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 5.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,487 shares of the computer hardware maker's stock after acquiring an additional 8,531 shares during the period. NVIDIA makes up about 2.9% of Octavia Wealth Advisors LLC's holdings, making the stock its 8th largest holding. Octavia Wealth Advisors LLC's holdings in NVIDIA were worth $28,826,000 as of its most recent filing with the Securities and Exchange Commission. Get NVIDIA alerts: Sign Up Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Center for Financial Planning Inc. boosted its position in shares of NVIDIA by 4.6% during the 2nd quarter. Center for Financial Planning Inc. now owns 8,429 shares of the computer hardware maker's stock worth $1,332,000 after acquiring an additional 367 shares in the last quarter. Svenska Handelsbanken AB publ purchased a new stake in NVIDIA during the third quarter worth approximately $37,316,000. Atria Investments Inc boosted its holdings in NVIDIA by 3.2% in the second quarter. Atria Investments Inc now owns 942,208 shares of the computer hardware maker's stock valued at $148,859,000 after purchasing an additional 29,479 shares in the last quarter. MADDEN SECURITIES Corp increased its stake in NVIDIA by 3.2% in the second quarter. MADDEN SECURITIES Corp now owns 81,322 shares of the computer hardware maker's stock valued at $12,848,000 after purchasing an additional 2,484 shares during the last quarter. Finally, Whalen Wealth Management Inc. raised its holdings in NVIDIA by 20.3% during the third quarter. Whalen Wealth Management Inc. now owns 36,490 shares of the computer hardware maker's stock worth $6,808,000 after purchasing an additional 6,162 shares in the last quarter. 65.27% of the stock is...
Key Points Nvidia has become an unquestioned leader in the AI revolution. That has translated to huge returns for shareholders over the past several years. 10 stocks we like better than Nvidia › In just a few short years, Nvidia (NASDAQ: NVDA) has grown from promising tech business to semiconductor industry leader to the biggest company in the world. At the beginning of the COVID pandemic, the sto...
Key Points Nvidia has become an unquestioned leader in the AI revolution. That has translated to huge returns for shareholders over the past several years. 10 stocks we like better than Nvidia › In just a few short years, Nvidia (NASDAQ: NVDA) has grown from promising tech business to semiconductor industry leader to the biggest company in the world. At the beginning of the COVID pandemic, the stock had a market cap of around $150 billion. Today, that number is around $4.5 trillion. You don't get to that point without delivering some big returns for shareholders. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Those returns haven't come in a straight line, though. Nvidia stock made relatively steady progress up until 2018. The "mini-bear" market in the fourth quarter of that year, which was fueled by recession concerns, resulted in the share price dropping by more than half. The COVID pandemic led to a sharp decline in the stock's price, followed by a quick rebound, but it was the 2022 bear market that did the most damage. From peak to valley, Nvidia fell by more than 60%. If you managed to ride all of that out over the past decade, the rewards would have been immense. For the decade ending Jan. 23, Nvidia stock gained more than 27,000%! That means a simple $100 investment made in Nvidia stock 10 years ago and held for the duration would have turned into $27,100. The next 10 years are unlikely to produce those same returns, but there's still reason to be optimistic. The AI revolution is still in the early innings and there's a lot of development still to be done. Nvidia has demonstrated its ability to be a leader in this space and should continue to be for the foreseeable future. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are...
Prior to the Oracle of Omaha's retirement as CEO, he jettisoned nearly 465 million shares of Bank of America and built an 8.8% stake in a beloved consumer brand that's skyrocketed 6,700% since its debut. For decades, few investors captivated the attention of professional and everyday investors quite like Berkshire Hathaway's (BRK.A +1.19%)(BRK.B +0.78%) billionaire boss, Warren Buffett. During his...
Prior to the Oracle of Omaha's retirement as CEO, he jettisoned nearly 465 million shares of Bank of America and built an 8.8% stake in a beloved consumer brand that's skyrocketed 6,700% since its debut. For decades, few investors captivated the attention of professional and everyday investors quite like Berkshire Hathaway's (BRK.A +1.19%)(BRK.B +0.78%) billionaire boss, Warren Buffett. During his roughly six-decade tenure at the helm, the Oracle of Omaha oversaw a nearly 6,100,000% cumulative return in Berkshire's Class A shares (BRK.A). Practically doubling the annualized total return, including dividends, of the benchmark S&P 500 since the mid-1960s made him an instant hit with investors. While Warren Buffett remains the chairman of Berkshire's board, he officially stepped down from the CEO role at the end of 2025 and handed the baton to his predetermined successor, Greg Abel. But just because he's no longer overseeing his trillion-dollar company's day-to-day operations, it doesn't mean Buffett stopped making moves to position Berkshire Hathaway for success before he retired. Thanks to Form 13F filings with the Securities and Exchange Commission, we know what Buffett was up to in the quarters leading up to his retirement. A 13F is a required filing for institutional investors with at least $100 million in assets under management that details which stocks Wall Street's smartest and most successful money managers have been buying and selling. One of the more eyebrow-raising moves leading up to Buffett's departure was his persistent selling of a core holding: Bank of America (BAC +0.23%). While Berkshire's outgoing boss was significantly reducing his company's stake in BofA, as Bank of America is commonly known, he was also building a position in a beloved consumer brand for five consecutive quarters (through Sept. 30, 2025). Investing legend Warren Buffett cashes in his chips on Bank of America For the better part of the last decade, Bank of America has been a top-...
London ( UKX ) -0.27% to 10,197. Germany ( DAX:IND ) -0.06% to 24,523, Germany retail sales edge higher in December. Germany's manufacturing PMI climbs to 49.1 in January, surpassing expectations. France ( CAC:IND ) -0.15% to 8,096, France manufacturing PMI rises to 43-month high. Euro Area manufacturing PMI hits 2-month high at 49.5 in January . In other parts of Europe, Spain's manufacturing sec...
London ( UKX ) -0.27% to 10,197. Germany ( DAX:IND ) -0.06% to 24,523, Germany retail sales edge higher in December. Germany's manufacturing PMI climbs to 49.1 in January, surpassing expectations. France ( CAC:IND ) -0.15% to 8,096, France manufacturing PMI rises to 43-month high. Euro Area manufacturing PMI hits 2-month high at 49.5 in January . In other parts of Europe, Spain's manufacturing sector sees a downturn in January. Poland’s S&P Global Manufacturing PMI edged up to 48.8 in January. Sweden’s Swedbank Manufacturing PMI rose to 56.0 in January. Retail sales in Switzerland rose by 2.9% Y/Y in December. The pan-European Stoxx 600 ( STOXX ) moved 0.42% lower to 608.3, sinking at the start of February, following a global market rout and a broad risk-off move. Commodity prices tumbled, and concerns over elevated AI valuations resurfaced. A broad sell-off in commodities hit miners across the board, while oil majors also slipped as crude prices fell. The euro was little changed at around $1.185 at the start of February, hovering near a four-year peak of $1.20 touched last week. Coming up in the session: UK's Manufacturing PMI numbers lined up shortly. In the bond market , the U.S. 10-year Treasury yield was down 1 basis point to 4.23%. Germany's 10-year yield was up 1 basis point to 2.85%. UK's 10-year yield was down 1 basis point to 4.51%. Currencies: ( EUR:USD ) ( GBP:USD ) ( CHF:USD ) ETFs: (NYSEARCA: EWG ), (NYSE: GF ), (NYSEARCA: EWI ), (NYSEARCA: EWQ ), (NASDAQ: FGM ), (NASDAQ: DAX ), (NYSEARCA: FLGR ), (NYSEARCA: FXB ), (NYSEARCA: EWU ), (NASDAQ: FKU ), (BATS: EWUS ), (NYSEARCA: FLGB ), (NYSEARCA: GREK ) More on Europe U.S. Dollar Stakes Get Raised - What To Do Now In The Rates Space? Technical Levels For Major FX Pairs Ahead Of The FOMC Rate Decision DAX: What To Know About The ETF That Tracks The 'S&P 500' Of Germany Germany retail sales edge higher in December Germany’s inflation rises to 2.1% in January from 1.8% in December 2025
Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to benefit. Here's where this company will be going, and where it's probably going to end up. It's hard to see thi...
Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to benefit. Here's where this company will be going, and where it's probably going to end up. It's hard to see this business getting any smaller In the next five years, expect AbbVie to continue to compete in the disease areas that its pipeline and product mix are currently heavily focused around: immunology, neuroscience, and oncology. It'll also likely continue to compete at a much smaller scale in aesthetics, eye medicines, and a grouping of other areas like infectious disease, but these efforts are ancillary at most. Given the 14 early-stage oncology programs it has that are currently in clinical trials, cancer drugs will probably be more important to the top line than they have been in the past. As shown by its recent acquisition of Cerevel, which it justified as bolstering its neuroscience portfolio, it wouldn't be too surprising to see AbbVie pursue more acquisitions, with an eye toward oncology or perhaps immunology. It currently has more than $7.2 billion in cash, equivalents, and short-term investments, and in 2023 it reported free cash flow (FCF) of nearly $22.1 billion. So it should have enough money and cash flow to buy a handful of small biotechs outright, or even a couple of larger ones if it's willing to lean on a bit of debt financing. Presently, management calculates that the company's top line will expand with a compound annual growth rate of between 7% and 9% from 2024 through 2029. Driving that growth will be $27 billion in revenue from its leading immunology drugs, Rinvoq and Skyrizi, an aesthetics portfolio worth more than $9 billion annually, and a recovering oncology segment that should start growing instead of shrinking within roughly the next two years. A few...
Translate webpages in Chrome: On your computer, open Chrome. Go to a webpage written in another language. At the top, click Translate. Chrome will translate the webpage one time. If you haven't installed Google Chrome. Please download and install it. Down
Translate webpages in Chrome: On your computer, open Chrome. Go to a webpage written in another language. At the top, click Translate. Chrome will translate the webpage one time. If you haven't installed Google Chrome. Please download and install it. Down
Monty Rakusen Manufacturing PMI in the Euro Area increased to a 2-month high of 49.50 points in January from 48.80 points in December of 2025. Production growth reinstated following first fall in output for ten months during December. Manufacturing output across the euro area increased in January for the tenth time over the past 11 months, but production growth lacked vigour as new factory orders ...
Monty Rakusen Manufacturing PMI in the Euro Area increased to a 2-month high of 49.50 points in January from 48.80 points in December of 2025. Production growth reinstated following first fall in output for ten months during December. Manufacturing output across the euro area increased in January for the tenth time over the past 11 months, but production growth lacked vigour as new factory orders fell since December. Meanwhile, job losses were extended, and firms reduced their buying quantities, although the downturn in purchasing volumes was only marginal. Nevertheless, business confidence rose to its highest level since February 2022. Elsewhere, pricing power appeared to be limited among eurozone manufacturers, with charges broadly unchanged on the month despite input cost inflation accelerating to a three-year high. ETFs: ( NYSEARCA: EWG ), ( NYSE: GF ), ( NYSEARCA: EWI ), ( NYSEARCA: EWQ ), ( NASDAQ: FGM ), ( DAX ) Currency: ( EUR:USD ) More on Eurozone, etc. U.S. Dollar Stakes Get Raised - What To Do Now In The Rates Space? Technical Levels For Major FX Pairs Ahead Of The FOMC Rate Decision EUR/USD Hints A Breakout After Latest Trump-Greenland Chaos (Technical Analysis) Germany retail sales edge higher in December Germany’s inflation rises to 2.1% in January from 1.8% in December 2025
Polish director-writer Michal Grzybowski’s film has inspired flashes, but mostly eschews humour for a drearier take on the intertwining of stage and life The play’s the thing in this tepid Polish comedy-drama that catches the conjugal complications of its protagonist. Self-righteous theatre actor Marcin (Łukasz Simlat), is mid-run playing Captain Hook in a production of Peter Pan. His terminally u...
Polish director-writer Michal Grzybowski’s film has inspired flashes, but mostly eschews humour for a drearier take on the intertwining of stage and life The play’s the thing in this tepid Polish comedy-drama that catches the conjugal complications of its protagonist. Self-righteous theatre actor Marcin (Łukasz Simlat), is mid-run playing Captain Hook in a production of Peter Pan. His terminally unhappy wife Ola (Agnieszka Duleba-Kasza) announces she is off; then, as their argument spills into the theatre wings where she is playing Tinkerbell, she reveals that she previously slept with someone else. Ziemovit/Peter Pan (Dobromir Dymecki) looks sheepish – before being opportunely hoisted out of reach on wires. A few months down the line, Marcin is essaying Torvald in Ibsen’s A Doll’s House opposite his new love Ewa (Wiktoria Filus) as Nora. But when she falls down a trapdoor, guess who is substituted into the role? The tension is ratcheted up when Marcin and Ola once again find themselves leading the bill as sparring Oberon and Titania, in a production of A Midsummer Night’s Dream on which their company’s future rests. Continue reading...